Tg-rasH2 mouse

A Tg-rasH2 mouse is an innovative transgenic mouse, developed in Central Institute for Experimental Animals (CIEA), carrying the three copies of human prototype c-Ha-ras oncogenes with endogenous promoter and enhancer in tandem. [ [http://www.ciea.or.jp/English/A1_R&D_rasH2.htm Central Institute for Experimental Animals ] ] Under Alternative Carcinogenicity Testing (ACT) project conducted by International Life Sciences Institute (ILSI) and ILSI Health and Environmental Sciences Institute (HESI), comprehensive evaluation studies on the Tg-rasH2 mouse bioassay system were performed and the usefulness of the system was validated for carcinogenicity studies by 23 international pharmaceutical companies. [ [http://www.ciea.or.jp/rash/background_data.htm#1 Background Data ] ] In the studies, it was confirmed that Tg-rasH2 mice are sensitive to both genotoxic and non-genotoxic human carcinogens and show no response to non-carcinogens. [ [http://www.ciea.or.jp/rash/tumorigenesis.htm#2 Tumorigenesis Patterns ] ] As a consequence, the Tg-rasH2 mice have been accepted as a short-term carcinogenicity study system enabling to reduce the conventional two-year study period to 26 weeks.

History

Characteristics

ee also

*ras gene
*hras

References

External links

* [http://www.ciea.or.jp/English/A1_R&D_rasH2.htm Tg-rasH2 mouse]